Spotlight
Clinical
CME
Partners
Macugen approval process moves forward
Eyetech Pharmaceuticals Inc. and Pfizer Inc. have filed a new drug application with the FDA for the 0.3 mg dose of pegaptanib sodium injection (Macugen) as a treatment for AMD (also see Page 46 in this issue).
Related Videos
Related Content
